Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.53 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.48 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.47 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.47 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.47 |
| ▸ | GAPDH | P04406 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | STAT6 | P42226 | 1/20 | 0.47 |
| ▸ | PI4KA | P42356 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2912972 | 0.91 | LMNA (0.55) | LMNATP53ADORA2AADORA2BHPGD | |
| SCHEMBL2912997 | 0.79 | ADORA2A (0.53) | LMNATP53ADORA2AADORA2BADORA1 | |
| SCHEMBL2913810 | 0.76 | KDM4E (0.50) | LMNATP53ADORA2AADORA2BSMN1; SMN2 | |
| SCHEMBL4081006 | 0.76 | SLC29A1 (0.70) | ADORA2AADORA2BADORA1ADORA3DPP4 | |
| SCHEMBL1979130 | 0.76 | SLC29A1 (0.70) | ADORA2AADORA2BADORA1ADORA3DPP4 | |
| SCHEMBL9142042 | 0.76 | SLC29A1 (0.70) | ADORA2AADORA2BADORA1ADORA3DPP4 | |
| SCHEMBL6903709 | 0.76 | SLC29A1 (0.70) | ADORA2AADORA2BADORA1ADORA3DPP4 | |
| SCHEMBL6887353 | 0.76 | SLC29A1 (0.70) | ADORA2AADORA2BADORA1ADORA3DPP4 | |
| SCHEMBL6314487 | 0.75 | LMNA (0.60) | LMNATP53ADORA2AADORA2BHPGD | |
| SCHEMBL14030783 | 0.74 | ADORA2A (0.78) | ADORA2AADORA2BADORA1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9186369-B2 | Purine nucleoside analogues for treating flaviviridae including hepatitis C | IDENIX PHARMACEUTICALS, LLC (US) | 2015-11-17 | — | — | US | disclosed |
| US-20140234251-A1 | PURINE NUCLEOSIDE ANALOGUES FOR TREATING FLAVIVIRIDAE INCLUDING HEPATITIS C | INDENIX PHARMACEUTICALS, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-8742101-B2 | Purine nucleoside analogues for treating flaviviridae including hepatitis C | IDENIX PHARMACEUTICALS, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| EP-1658302-B1 | PURINE NUCLEOSIDE ANALOGUES FOR TREATING DISEASES CAUSED BY FLAVIVIRIDAE INCLUDING HEPATITIS C | IDENIX PHARMACEUTICALS INC (US) | 2010-08-25 | — | — | EP | disclosed |
| US-20090169507-A1 | PURINE NUCLEOSIDE ANALOGUES FOR TREATING FLAVIVIRIDAE INCLUDING HEPATITIS C | IDENIX PHARMACEUTICALS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20050075309-A1 | Treatment of pestivirus, flavivirus and hepatitis C virus infection by administering tan effective amount of an anti-HCV biologically active pentofuranonucleoside where the pentofuranonucleoside base is an optionally substituted 2-azapurine;viricides; nontoxic; side effects reduction | IDENIX PHARMACEUTICALS, INC. | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140234251-A1 | PURINE NUCLEOSIDE ANALOGUES FOR TREATING FLAVIVIRIDAE INCLUDING HEPATITIS C | PNP, TPMT, MTAP | LMNA 2831/4885TP53 2974/4885ADORA2A 112/4885 |
| US-20090169507-A1 | PURINE NUCLEOSIDE ANALOGUES FOR TREATING FLAVIVIRIDAE INCLUDING HEPATITIS C | PNP, TPMT, MTAP | LMNA 2831/4885TP53 2974/4885ADORA2A 112/4885 |
| US-20050075309-A1 | Treatment of pestivirus, flavivirus and hepatitis C virus infection by administering tan effective amount of an anti-HCV biologically active pentofuranonucleoside where the pentofuranonucleoside base is an optionally substituted 2-azapurine;viricides; nontoxic; side effects reduction | PNP, TPMT, HAVCR2 | LMNA 3686/4885TP53 2924/4885ADORA2A 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.